A detailed history of Baystate Wealth Management LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Baystate Wealth Management LLC holds 76 shares of VRTX stock, worth $36,036. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76
Previous 51 49.02%
Holding current value
$36,036
Previous $17,000 76.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 29, 2024

BUY
$343.0 - $410.68 $8,575 - $10,267
25 Added 49.02%
76 $30,000
Q3 2023

Oct 25, 2023

SELL
$338.18 - $362.46 $338 - $362
-1 Reduced 1.92%
51 $17,000
Q2 2023

Sep 21, 2023

SELL
$314.42 - $351.91 $191,167 - $213,961
-608 Reduced 92.12%
52 $18,000
Q2 2023

Aug 02, 2023

BUY
$314.42 - $351.91 $191,481 - $214,313
609 Added 1194.12%
660 $232,000
Q1 2023

Apr 25, 2023

SELL
$283.23 - $323.1 $849 - $969
-3 Reduced 5.56%
51 $16,000
Q4 2022

Jan 12, 2023

BUY
$285.76 - $321.48 $857 - $964
3 Added 5.88%
54 $16,000
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $27,383 - $30,552
-100 Reduced 66.23%
51 $15,000
Q3 2021

Nov 05, 2021

SELL
$181.39 - $202.99 $544 - $608
-3 Reduced 1.95%
151 $27,000
Q1 2021

Apr 21, 2021

SELL
$207.02 - $241.31 $141,601 - $165,056
-684 Reduced 81.62%
154 $33,000
Q4 2020

Jan 15, 2021

BUY
$207.01 - $276.09 $141,594 - $188,845
684 Added 444.16%
838 $198,000
Q3 2020

Oct 14, 2020

BUY
$255.65 - $303.1 $766 - $909
3 Added 1.99%
154 $42,000
Q2 2020

Jul 28, 2020

BUY
$225.48 - $295.8 $9,244 - $12,127
41 Added 37.27%
151 $44,000
Q3 2017

Oct 10, 2017

BUY
$148.13 - $162.24 $16,294 - $17,846
110
110 $17,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $122B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Baystate Wealth Management LLC Portfolio

Follow Baystate Wealth Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baystate Wealth Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Baystate Wealth Management LLC with notifications on news.